Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
23-26 March, 2026
Global ChemShowGlobal ChemShow
Not Confirmed
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
23-26 March, 2026
Global ChemShowGlobal ChemShow
Industry Trade Show
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Digital content

16 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251216955463/en/Vir-Biotechnology-Grants-Norgine-Exclusive-Commercial-License-to-Chronic-Hepatitis-Delta-Treatment-Candidate-in-Europe-Australia-New-Zealand-Including-Global-Cost-Sharing-Agreement-for-Ongoing-ECLIPSE-Clinical-Development-Program

14 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/norgine-completes-acquisition-of-theravia-302529332.html

09 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/swissmedic-approves-ifinwil-eflornithine-for-children-diagnosed-with-high-risk-neuroblastoma-hrnb-302499271.html

17 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/norgine-welcomes-tga-registration-in-australia-of-ifinwil-eflornithine-for-adults-and-children-diagnosed-with-high-risk-neuroblastoma-hrnb1-302430883.html

15 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/norgine-strengthens-rare-disease-portfolio-with-acquisition-of-theravia-302427963.html

24 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/x4-pharmaceuticals-announces-ema-validation-of-marketing-authorization-application-maa-for-mavorixafor---licenced-to-norgine-for-commercialisation-in-europe-302359812.html
ABOUT THIS PAGE